Ország: Írország
Nyelv: angol
Forrás: HPRA (Health Products Regulatory Authority)
VENLAFAXINE HYDROCHLORIDE
Ranbaxy (UK) Limited
VENLAFAXINE HYDROCHLORIDE
150 Milligram
Prolonged Release Capsules
Product subject to prescription which may not be renewed (A)
Withdrawn
2012-03-20
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Velexor XL 150 mg prolonged Release-Capsules, Hard 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each Velexor XL 150 mg Prolonged-Release Capsule, Hard contains 169.71 mg venlafaxine hydrochloride, equivalent to 150mg Venlafaxine For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Prolonged-Release Capsule, Hard Size “0” capsule with caramel opaque cap and body imprinted with RVn on the cap and 150 on the body in black ink 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of major depressive episodes. For prevention of recurrence of major depressive episodes. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _MAJOR DEPRESSIVE EPISODES_ The recommended starting dose for Velexor XL is 75 mg given once daily. Patients not responding to the initial 75 mg/day dose may benefit from dose increases up to a maximum dose of 375 mg/day. Dosage increases can be made at intervals of 2 weeks or more. If clinically warranted due to symptom severity, dose increases can be made at more frequent intervals, but not less than 4 days. Because of the risk of dose-related adverse effects, dose increments should be made only after a clinical evaluation (see section 4.4). The lowest effective dose should be maintained. Patients should be treated for a sufficient period of time, usually several months or longer. Treatment should be reassessed regularly on a case-by-case basis. Longer-term treatment may also be appropriate for prevention of recurrence of major depressive episodes (MDE). In most of the cases, the recommended dose in prevention of recurrence of MDE is the same as the one used during the current episode. Antidepressive medicinal products should continue for at least six months following remiss Olvassa el a teljes dokumentumot